2018 Gastritis (stomach inflammation) Drug Development- Pipeline Analysis Report

May 2018 | | ID: 2BE2ABD97C7EN
VPAResearch

Abstracts

Gastritis is the inflammation of mucosa, lining of stomach, that can last for shorter periods or longer durations. Infection, alcohol and intake of NSAIDs lead to gastritis. Without treatment, it can lost for few years. The market presents robust business growth opportunity.

Around 20 companies and universities are focusing on developing treatment options for Gastritis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Gastritis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Gastritis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Gastritis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 GASTRITIS (STOMACH INFLAMMATION) PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Gastritis (stomach inflammation) Pipeline Snapshot
2.3 Gastritis (stomach inflammation) Pipeline by Phase
2.4 Gastritis (stomach inflammation) Pipeline by Company
2.5 Gastritis (stomach inflammation) Pipeline by Mechanism of Action

3 GASTRITIS (STOMACH INFLAMMATION)- COMPANY WISE PIPELINE ANALYSIS

Allakos, Inc.
AstraZeneca
Boryung Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co. LTD.
Recce Ltd
RedHill Biopharma Ltd
Sequella Inc
Trio Medicines Ltd

4 GASTRITIS (STOMACH INFLAMMATION) R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN GASTRITIS (STOMACH INFLAMMATION) PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Gastritis (stomach inflammation) Pipeline by Phase, H1- 2018
Figure 2: Gastritis (stomach inflammation) Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Gastritis (stomach inflammation) Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Gastritis (stomach inflammation) Pipeline by Phase, H1- 2018
Table 2: Gastritis (stomach inflammation) Pipeline by Companies, H1- 2018
Table 3: Gastritis (stomach inflammation) Pipeline by Mechanism of Action, H1- 2018
Table 4: Allakos, Inc. Gastritis/stomach inflammation pipeline, May 2018
Table 5: AstraZeneca Gastritis/stomach inflammation pipeline, May 2018
Table 6: Boryung Pharmaceutical Co Ltd Gastritis/stomach inflammation pipeline, May 2018
Table 7: Daewoong Pharmaceutical Co. LTD. Gastritis/stomach inflammation pipeline, May 2018
Table 8: Recce Ltd Gastritis/stomach inflammation pipeline, May 2018
Table 9: RedHill Biopharma Ltd Gastritis/stomach inflammation pipeline, May 2018
Table 10: Sequella Inc Gastritis/stomach inflammation pipeline, May 2018
Table 11: Trio Medicines Ltd Gastritis/stomach inflammation pipeline, May 2018